Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT314 in Advanced Malignant Solid Tumors
NCT06150183Phase 1Active, not recruiting
- Sponsor
- BioNTech SE
- Start
- Nov 2023
- Primary completion
- Aug 2026
- Modality
- Bispecific Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of GEN1059 in solid tumor, sponsored by BioNTech SE. Primary endpoints: Occurrence of dose-limiting toxicity at 21 days, Treatment-emergent adverse events at 90 days and 2 more. Started Nov 2023; status: active, not recruiting.
02
Drugs
GEN1059
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06150183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06150183.